Vir Biotechnology, Inc.: directors' dealings · United States · SEC (Form 4)

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a United States-based biopharmaceutical company listed on the Nasdaq market in the United States, focused on discovering and developing therapies for serious infectious diseases, with a more recent expansion into selected oncology applications. Founded in 2016 and headquartered in San Francisco, California, the company was built around a technology-driven approach that combines antibodies, immunology, and protein-masking platforms to generate differentiated therapeutic candidates. ([stockanalysis.com](https://stockanalysis.com/stocks/vir/company/?utm_source=openai)) From a historical perspective, Vir Biotechnology initially established its identity around high-unmet-need viral diseases. Its portfolio has long included programs in hepatitis B, hepatitis delta, HIV, influenza, and COVID-19, spanning preclinical work through more advanced clinical stages. In its recent communications, the company has signaled a more selective and partnership-oriented strategy, while remaining open to out-licensing discussions for several programs, including hepatitis B, influenza, COVID-19, and HPV. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1706431/000162828024006852/vir-20231231.htm?utm_source=openai)) In competitive terms, Vir operates in a highly contested field populated by large pharmaceutical companies and numerous specialized biotech peers in immunology and infectious disease. Its competitive edge is centered on the scientific quality of its platform, the depth of its translational research, and its ability to structure partnerships with major industry players. The company has used licensing and collaboration agreements to support asset monetization while reducing the burden of funding the full pipeline on a standalone basis. ([investors.vir.bio](https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx?utm_source=openai)) Among the most notable recent developments, Vir Biotechnology announced in 2025 first-in-human dosing of VIR-5525, a masked EGFR-targeting T-cell engager for solid tumors, highlighting a diversification beyond infectious diseases. The company also released its 2025 full-year results in 2026, underscoring active capital management and continued clinical progress. For French-speaking investors, the key question remains whether Vir can convert a scientifically promising platform into durable clinical, and eventually commercial, value creation in a highly selective Nasdaq biotech environment. ([investors.vir.bio](https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx?utm_source=openai))